Nowadays excessively used corticosteroids in veterinary medicine induce steroid hepatopathy in dogs (Canis lupus familiaris). The objective of this study was to determine the possibility of the hepatoprotectants to decrease the corticosteroid-induced alteration in such dogs’ blood serum enzymes as alaninaminotransferase (ALAT), gammaglutamyltranferase (GGT), alkaline phosphatase (AP) and corticosteroid-induced thermostable alkaline phosphatase (cAP). The study took place in private veterinary clinics in Riga, Latvia, during 2013, with the permission of dogs’ owners. Twenty eight animals, which received corticosteroids due to present diagnosis, were divided into two groups. In the first group long-lasting corticosteroid methylprednisolone acetate injection was used once, while in the second group the hepatoprotectants were used after the injection of corticosteroids. It was discovered that after 14 and after 30 days of hepatoprotectants use, blood enzymes were significantly lower (p is less than 0.05) than in dogs that did not receive hepatoprotectants. In both groups the enzyme values did not reach the reference limits. The study is set to investigate further if and when the values reach the reference limits.

This article summarizes data of determining a therapeutic dose of a new immunocorrecting drug, dermatocytoglobulin, developed by the authors of this study. It has been established that this drug has a therapeutic immunocorrecting effect on allergic dermatitis. Subjects of the study cattle, horses, of Raimbek – Commercial Diary Farm, 56 dogs and 35 cats admitted to a veterinary clinic. It has been established that administration of dermatocytoglobulin in trial groups reduces autoantibody titers until their elimination on the 12th day, dose of 0.2 cm3 per 10 kg while autoantibody titers in control groups were identified on the 30th day.

Competitiveness is the key factor in order to reach the economic transformation, smart growth, governance and legal framework for the state and society for sustainable development that are stated as the major goals in the current planning period in Latvia. High-technology industries are the main drivers of economic activity in developed economies. To ensure data comparability, the official definition of the high-technology industries by Eurostat is applied in this research including two industries: manufacture of basic pharmaceutical products and pharmaceutical preparations and manufacture of computer, electronic and optical products. The research aims to analyse high-technology industries in Latvia taking into account the competitiveness and the regional allocation using a set of several indicators. According to NUTS 3, Latvia is subdivided into 6 regions; however, the high-technology industries are regionally allocated mainly in two regions, Riga and Pieriga regions. Manufacture of basic pharmaceutical products etc. employs 99% of employees in these two regions, manufacture of computer etc. products – 81% despite the fact that only 54% of employees reside in these two regions. The research confirms that the high-technology regional allocation depends on available labour resources and also education and professional training facilities in the region. We conclude that the high-technology industries are competitive in the global market as the share of the high-tech products in total exports is several times higher than the share of these industries in the manufacturing sector or in total economy. The global competitiveness of Latvia’s high-tech industries is stable and gradually rising.